Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial

Diabetologia

Volumn 59, Issue 10, 2016, Pages 2181-2192

  Vlassara, Helen ^a   Cai, Weijing ^a   Tripp, Elizabeth ^a   Pyzik, Renata ^a   Yee, Kalle ^a   Goldberg, Laurie ^a   Tansman, Laurie ^a   Chen, Xue ^a   Mani, Venkatesh ^a   Fayad, Zahi A ^a   Nadkarni, Girish N ^a   Striker, Gary E ^a   He, John C ^a   Uribarri, Jaime ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

AGER1; Cardiovascular disease; Diabetes; Glycotoxins; Inflammation; Innate defence; RAGE; SIRT1

Indexed keywords

8 ISOPROSTANE; ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR 1; HEMOGLOBIN A1C; INSULIN; LACTOYLGLUTATHIONE LYASE; MESSENGER RNA; SIRTUIN 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; GLUCOSE BLOOD LEVEL;

ABDOMINAL SUBCUTANEOUS FAT; ADULT; AGE; ARTICLE; BLOOD SAMPLING; CAROTID ARTERY; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; HUMAN; HUMAN CELL; INSULIN RESISTANCE; INTRAPERITONEAL FAT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; URINE SAMPLING; WEIGHT REDUCTION; 3T3-L1 CELL LINE; AGED; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GENETICS; GLUCOSE BLOOD LEVEL; INFLAMMATION; METABOLISM; MIDDLE AGED; MOUSE; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; WAIST CIRCUMFERENCE; WESTERN BLOTTING;

3T3-L1 CELLS; AGED; AGED, 80 AND OVER; ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MICE; MIDDLE AGED; OBESITY; OXIDATIVE STRESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; WAIST CIRCUMFERENCE;

EID: 84980002652     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4053-x     Document Type: Article

References (39)

1. Amos AF, McCarty DJ, Zimmet P (1997) The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14(Suppl 5):S1–S85
2. Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D’Agostino RB Sr (2006) Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation 113:2914–2918
3. Jason J, Laedtke T, Parisis JE, O’Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53:474–481
4. Ford ES, Giles WH, Mokdad AH (2004) Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 27:2444–2449
5. Lutsey PL, Steffen LM, Stevens J (2008) Dietary intake and the development of the metabolic syndrome: the Atherosclerosis Risk in Communities study. Circulation 117:754–761
6. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:860–867
7. Roberson LL, Aneni EC, Maziak W et al (2014) Beyond BMI: the ‘metabolically healthy obese’ phenotype, its association with clinical/subclinical cardiovascular disease and all-cause mortality—a systematic review. BMC Public Health 14:14
8. Stefan N, Haring HU, Hu FB, Schulze MB (2013) Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol 1:152–162
9. Hankinson AL, Daviglus ML, Van Horn L et al (2013) Diet composition and activity level of at risk and metabolically healthy obese American adults. Obesity (Silver Spring) 21:637–643
10. Mozzafarian D, Ludwig D (2015) The 2015 US dietary guidelines: lifting the ban on total dietary fat. JAMA 313:2421–2422
11. Chowdhury R, Warnakula S, Kunutsor S et al (2014) Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med 160:398–406
12. Cai W, Gao QD, Zhu L, Peppa M, He C, Vlassara H (2002) Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 8:337–346
13. Vlassara H, Striker GE (2011) AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol 7:526–539
14. Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H (2012) Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci U S A 109:15888–15893
15. Uribarri J, Woodruff S, Goodman S et al (2010) Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 110:911–916
16. Birlouez-Aragon I, Saavedra G, Tessier FJ et al (2010) A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr 91:1220–1226
17. Uribarri J, Cai W, Ramdas M et al (2011) Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 34:1610–1616
18. Mark AB, Poulsen MW, Andersen S et al (2014) Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. Diabetes Care 37:88–95
19. Vlassara H, Cai W, Goodman S et al (2009) Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab 94:4483–4491
20. Uribarri J, Cai W, Woodward M et al (2015) Elevated serum advanced glycation endproducts in obese indicate risk for the metabolic syndrome: a link between healthy and unhealthy obese? J Clin Endocrinol Metab 100:1957–1966
21. NCEP (2002) Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421
22. Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419
23. Bonekamp S, Ghosh P, Crawford S et al (2008) Quantitative comparison and evaluation of software packages for assessment of abdominal adipose tissue distribution by magnetic resonance imaging. Int J Obes (Lond) 32:100–111
24. Fayad ZA, Mani V, Woodward M et al (2011) Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 378:1547–1559
25. Makita Z, Vlassara H, Cerami A, Bucala R (1992) Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267:5133–5138
26. Mitsuhashi T, Vlassara H, Founds HW, Li YM (1997) Standardizing the immunological measurement of advanced glycation endproducts using normal human serum. J Immunol Methods 207:79–88
27. Cai W, Uribarri J, Zhu L et al (2014) Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci U S A 111:4940–4945
28. Yoshizaki T, Schenk S, Imamura T et al (2010) SIRT 1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab 298:E419–E428
29. Uribarri J, Cai W, Pyzik R et al (2014) Suppression of native defense mechanisms, SIRT1 and PPARγ, by dietary glycoxidants precedes disease in adult humans; relevance to lifestyle-engendered chronic diseases. Amino Acids 46:301–309
30. Liang F, Kume S, Koya D (2009) SIRT1 and insulin resistance. Nat Rev Endocrinol 5:367–373
31. Yoshizaki T, Milne JC, Imamura T et al (2009) SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 29:1363–1374
32. Guarente L (2011) Franklin H. Epstein lecture. Sirtuins, aging, and medicine. N Engl J Med 364:2235–2244
33. Torreggiani M, Liu H, Wu J et al (2009) Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia. Am J Pathol 175:1722–1732
34. Takemura Y, Ouchi N, Shibata R et al (2007) Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 117:375–386
35. de Kreutzenberg SV, Ceolotto G, Papparella I et al (2010) Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes 59:1006–1015
36. Brouwers O, Niessen PM, Ferreira I et al (2011) Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. J Biol Chem 286:1374–1380
37. Bucala R, Makita Z, Koschinsky T et al (1993) Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A 90:6634–6638
38. Scheijen JL, Clevers E, Engelen L et al (2016) Analysis of advanced glycation endproducts in selected food items by ultra-performance liquid chromatography tandem mass spectrometry: presentation of a dietary AGE database. Food Chem 190:1145–1150
39. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470